MARKET

ALBO

ALBO

Albireo Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.24
-0.76
-3.62%
After Hours: 20.24 0 0.00% 16:00 12/13 EST
OPEN
20.81
PREV CLOSE
21.00
HIGH
21.41
LOW
19.89
VOLUME
44.37K
TURNOVER
--
52 WEEK HIGH
38.69
52 WEEK LOW
16.13
MARKET CAP
256.78M
P/E (TTM)
-3.4982
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALBO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ALBO News

  • Albireo to Present at the Jefferies 2019 London Healthcare Conference
  • GlobeNewswire.11/14 13:30
  • Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/11 01:37
  • Were Hedge Funds Right About Souring On Albireo Pharma, Inc. (ALBO)?
  • Insider Monkey.11/06 19:51
  • The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings
  • Benzinga.11/06 13:21

More

Industry

Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Name
Price
%Change

About ALBO

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).
More

Webull offers Albireo Pharma Inc (ALBO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.